Clinical trials: Locally Advanced Colorectal Cancer
Rectal Neoplasms
CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision
Primary objective: Pathological complete response (ypT0N0) rate Secondary objectives: Histopathological R0 resection rate Pathological downstaging (ypT0-T2N0) rate One month surgical complication rate Predictive value of…
- Trial name
- NCT00174616
- Testing
- Oxaliplatin, capecitabine, radiotherapy
- Where
- 7 sites in Belgium, France and 5 more
- Volunteers
- 87 people
- Sponsor
- Sanofi
Colorectal Cancer
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
PURPOSE: Phase II trial to study the effectiveness of combining capecitabine and irinotecan in treating patients who have locally advanced, recurrent, or metastatic colorectal cancer.
- Trial name
- NCT00022698
- Testing
- Capecitabine, Irinotecan
- Where
- 17 sites in United States
- Volunteers
- 67 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
This is a multicenter, open-label study enrolling a total of up to 23 patients.
- Trial name
- NCT00873756
- Testing
- FOLFOX regimen, bevacizumab, dulanermin
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Genentech, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
This research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (MEK) Inhibitor) and SAR245409 (Phosphatidylinositol 3-kinase (Pi3K)/Mammalian…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01390818
- Testing
- MSC1936369B (pimasertib), SAR245409 (PI3K and mTOR inhibitor)
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 146 people
- Sponsor
- EMD Serono
Colorectal Carcinoma
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
In this study, participants with previously-treated locally-advanced unresectable or metastatic mismatched repair (MMR) deficient or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) will be treated with…
- Trial name
- NCT02460198
- Testing
- Pembrolizumab
- Volunteers
- 124 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Cancer, Solid Tumor
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
- Conditions
- Metastatic Cancer, Solid Tumor, Pancreatic Cancer, Urothelial Carcinoma
- Trial name
- NCT04666688
- Testing
- LYT-200, Tislelizumab, Gemcitabine/nab-paclitaxel
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- PureTech
Solid Tumor
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
- Trial name
- LODESTAR (NCT04171700)
- Testing
- Rucaparib
- Where
- 19 sites in United States
- Volunteers
- 83 people
- Sponsor
- pharmaand GmbH
Cancer, Colon Cancer
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
This is a phase 3, randomized, double-blind, placebo-controlled multi-center study evaluating the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia (FN) in patients with newly diagnosed, locally-advanced or…
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Fever
- Trial name
- NCT00911170
- Testing
- Pegfilgrastim, Bevacizumab, Standard Chemotherapy
- Where
- 154 sites in United States, Australia and 15 more
- Volunteers
- 847 people
- Sponsor
- Amgen
Colorectal Cancer
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
The purpose of this clinical trial is to determine whether the combination of 5-fluorouracil (5-FU) plus a DAVANAT (carbohydrate polymer) along with Avastin and Leucovorin (LV) is beneficial in treating colorectal cancer in…
- Trial name
- NCT00388700
- Testing
- GM-CT-01, 5-Fluorouracil, Leukovorin, bevacizumab
- Where
- 4 sites in Israel
- Sponsor
- Galectin Therapeutics Inc.
Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer
A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors
1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies
- Conditions
- Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer, Cholangiocarcinoma
- Trial name
- NCT02990481
- Testing
- TRK-950
- Where
- 3 sites in United States, France
- Volunteers
- 38 people
- Sponsor
- Toray Industries, Inc
Unresectable Metastatic Colorectal Cancer, Unresectable Locally Advanced Colorectal Cancer
First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer
This is a phase I/IIA, first-in-human (FIH), two-part, open-label, multicenter study to characterize the safety, tolerability profile, and clinical efficacy of STC-1010 associated with GM-CSF and cyclophosphamide immunostimulant…
- Trial name
- NCT06934538
- Testing
- STC-1010 + IS regimen + SOC therapy
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 90 people
- Sponsor
- Brenus Pharma